Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)

Phase 1DIAG723Positive

AI Analysis

Summary

Diagonal Therapeutics announced first patient enrollment in its Phase 1/2 DIAMOND trial of DIAG723, a first-in-class clustering agonist antibody designed to restore ALK1 signaling in hereditary hemorrhagic telangiectasia (HHT).

Clinical Trial Data

Phase

1/2

Outcome Details

First patient dosed in Phase 1/2 DIAMOND clinical trial

Importance:5/10

Sentiment:

0.60

Phase 1/2 trialFirst-in-classClustering agonist antibodyRare diseaseALK1 signaling

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on July 16, 2026 10:30 AM

Read Original